University of Iowa Research Foundation

The United States Government As Represented by the Department of Veterans Affairs

Paloma H Giangrande

Francis G Miller

William Thiel

James O McNamara

Kevin Urak

George J Weiner

Anton P McCaffrey

Sue Blackwell

Kristina W Thiel

Suresh Veeramani

William M Rockey

The present invention relates to optimized aptamers and methods of using these aptamers.

Nucleic acid aptamers to treat histone-induced disease states

Disclosed herein are compositions including an aptamer bound to a complex, wherein the complex comprises at least two polypeptides. Accordingly, methods of using the aptamers and making the aptamers are also disclosed.

Nucleic acid aptamers

The present invention relates to methods of using optimized aptamers. In certain embodiments, the present invention provides a method for treating a subject having or being disposed to having a histone-induced injury or disease comprising administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and (i) a nucleic acid molecule not more than 90 nucleotides in length comprising an aptamer KU1, KU2, KU3, KU4, KU5, KU6, KU&, KU8, or KU9, wherein the aptamer specifically targets extracellular histones, wherein the nucleotides are RNA; or (ii) a conjugate comprising a nucleic acid molecule not more than 90 nucleotides in length comprising an aptamer KU1, KU2, KU3, KU4, KU5, KU6, KU&, KU8, or KU9, wherein the aptamer specifically targets extracellular histones, wherein the nucleotides are RNA, wherein the nucleic acid molecule is linked to a therapeutic molecule.

The present invention relates to optimized HER2 aptamers and methods of using these aptamers.

HER2 nucleic acid aptamers

Growing community of inventors

Iowa City, IA, United States of America

Paloma H Giangrande